表紙
市場調查報告書

全身性肥胖細胞症:開發中產品分析

Systemic Mastocytosis - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 253676
出版日期 內容資訊 英文 169 Pages
訂單完成後即時交付
價格
Back to Top
全身性肥胖細胞症:開發中產品分析 Systemic Mastocytosis - Pipeline Review, H2 2019
出版日期: 2019年12月16日內容資訊: 英文 169 Pages
簡介

全身性肥大細胞增生症是肥胖細胞以骨髓為首在複數的器官中異常增生的疾病。伴隨有呼吸急促、低血壓,蕁麻疹,腫起、發癢、下痢、頭痛、發熱、肌肉或骨骼疼痛等症狀。治療有使用抗組織胺藥物,若是在更具侵襲性的全身性肥大細胞增生症時,可使用干擾素和化療用醫藥品。

本報告提供全身性肥胖細胞症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

全身性肥胖細胞症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

全身性肥胖細胞症的治療藥開發企業

  • AB Science SA
  • AbbVie Inc
  • Arog Pharmaceuticals Inc
  • Blueprint Medicines Corp
  • Bristol-Myers Squibb Company
  • Deciphera Pharmaceuticals LLC
  • Novartis AG
  • Patara Pharma Inc
  • Seattle Genetics Inc
  • Stemline Therapeutics Inc

藥物簡介

全身性肥胖細胞症:開發中止的產品

全身性肥胖細胞症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11625IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2019, provides an overview of the Systemic Mastocytosis (Gastrointestinal) pipeline landscape.

Systemic mastocytosis is a disorder where mast cells are abnormally increased in multiple organs including the bone marrow. Symptoms include shortness of breath, low blood pressure, hives and swelling, itching, diarrhea, headache, flushing and musculoskeletal pain. Treatment includes antihistamines and more aggressive forms of Systemic mastocytosis require interferon or chemotherapeutic agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Mastocytosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Systemic Mastocytosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Mastocytosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Systemic Mastocytosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 4, 2 and 2 respectively.

Systemic Mastocytosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Mastocytosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Mastocytosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Mastocytosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Mastocytosis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Mastocytosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Mastocytosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Systemic Mastocytosis - Overview
  • Systemic Mastocytosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Systemic Mastocytosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Systemic Mastocytosis - Companies Involved in Therapeutics Development
  • AB Science SA
  • Allakos Inc
  • Arog Pharmaceuticals Inc
  • Blueprint Medicines Corp
  • Bristol-Myers Squibb Co
  • Deciphera Pharmaceuticals Inc
  • Seattle Genetics Inc
  • Stemline Therapeutics Inc
  • Systemic Mastocytosis - Drug Profiles
  • AK-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • avapritinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BLU-263 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brentuximab vedotin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • crenolanib besylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dasatinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • masitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ripretinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tagraxofusp - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Systemic Mastocytosis - Dormant Projects
  • Systemic Mastocytosis - Discontinued Products
  • Systemic Mastocytosis - Product Development Milestones
  • Featured News & Press Releases
  • Nov 25, 2019: AB Science provides the summary of webcast with Key opinion leaders on Indolent Systemic Mastocytosis
  • Nov 06, 2019: Blueprint Medicines to present initial data from phase 2 PIONEER trial of Avapritinib in patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
  • Nov 04, 2019: AB Science will host a live webcast on indolent systemic mastocytosis on November 20, 2019
  • Oct 24, 2019: AB Science granted authorization to initiate phase 3 confirmatory study of Masitinib in indolent systemic mastocytosis
  • Aug 12, 2019: AB Science to present at two upcoming conferences in September 2019
  • Aug 05, 2019: AB Science provides an update on its masitinib clinical program
  • Jun 15, 2019: Blueprint Medicines presents updated EXPLORER trial data for Avapritinib in patients with systemic mastocytosis at 24th EHA Congress
  • Jun 04, 2019: AB Science is providing a summary of the web conference held on 4 June 2019
  • May 16, 2019: Blueprint Medicines announces data presentations at ASCO and EHA meetings from registration-enabling clinical trials of Avapritinib across multiple patient populations
  • Mar 27, 2019: Blueprint Medicines announces updates on regulatory submission plans and recent clinical progress of Avapritinib
  • Feb 19, 2019: Allakos announces positive phase 1 results with AK002 in Indolent Systemic Mastocytosis
  • Dec 02, 2018: Blueprint Medicines announces updated results from ongoing EXPLORER clinical trial of Avapritinib demonstrating broad clinical activity and significant symptom reductions in patients with systemic mastocytosis
  • Jun 15, 2018: Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity
  • May 17, 2018: Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and Systemic Mastocytosis
  • Dec 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Mastocytosis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Systemic Mastocytosis - Pipeline by AB Science SA, H2 2019
  • Systemic Mastocytosis - Pipeline by Allakos Inc, H2 2019
  • Systemic Mastocytosis - Pipeline by Arog Pharmaceuticals Inc, H2 2019
  • Systemic Mastocytosis - Pipeline by Blueprint Medicines Corp, H2 2019
  • Systemic Mastocytosis - Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Systemic Mastocytosis - Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
  • Systemic Mastocytosis - Pipeline by Seattle Genetics Inc, H2 2019
  • Systemic Mastocytosis - Pipeline by Stemline Therapeutics Inc, H2 2019
  • Systemic Mastocytosis - Dormant Projects, H2 2019
  • Systemic Mastocytosis - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Systemic Mastocytosis, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top